Disease Markers

Stroke Biomarkers: Diagnosis, Prognosis, and Treatment


Publishing date
01 Dec 2022
Status
Closed
Submission deadline
15 Jul 2022

Lead Editor

1National Research Center for Rehabilitation Technical Aids, Beijing, China

2Manchester Metropolitan University, Manchester, UK

3Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

This issue is now closed for submissions.

Stroke Biomarkers: Diagnosis, Prognosis, and Treatment

This issue is now closed for submissions.

Description

Stroke is the second leading cause of death in the world and the overall global burden of stroke has increased in the past several decades in developing countries. Despite substantial progress in reperfusion therapies, such as intravenous (IV) thrombolysis and mechanical thrombectomy, more than 50% of patients with stroke continue to have a disability at 3 months after treatment.

Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. Careful assessment of the validity of biomarkers is required with respect to the stage of the disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory.

In this Special Issue, we welcome original research and review articles that discuss the current classification, diagnosis, and treatment of stroke, focusing on the use of novel biomarkers (either solitary markers or multiple markers within a panel) that have been studied in a variety of clinical settings. This Special Issue expects to develop the following biomarkers: tissue injury biomarkers [e.g., S100 calcium binding protein B (S-100B), neuron-specific enolase (NSE), myelin basic protein (MBP), and glial fibrillary acidic protein (GFAP), and other new finding biomarkers], inflammatory biomarkers [e.g., C-reactive protein (CRP), interleukin-6 (IL-6), tissue necross factor-alpha (TNF-α), vascular cell adhesion protein 1 (VCAM 1), inter-cellular adhesion molecule 1 (ICAM 1), N-methyl-d-aspartate (NMDA) receptor antibodies and matrix metalloproteinases (MMPs), and other new finding biomarkers], coagulation/thrombosis biomarkers (Fibrinogen, D-Dimer, vWF, and other new finding biomarkers), plasma DNA and RNA, myocardial metabolites (e.g., copeptin, B-type neurotrophic growth factor), adipose tissue metabolites[e.g., leptin, adiponectin, resistin, visfatin (from visceral fat), retinol-binding protein 4 (which induces insulin resistance), and vaspin (found in visceral fat and has insulin-sensitizing actions)], vitamin metabolites(e.g., vitamin D and vitamin A), oxidative stress biomarkers [e.g., malondialdehyde, F2-isoprostanes, and 8-Hydroxy-2-deoxyguanosine] and other new finding biomarkers. We expect to see multilevel omics for the discovery of biomarkers and therapeutic targets for stroke, particularly those that use creative and cutting-edge methodologies; papers that expand our understanding of the impacts of biomarkers on stroke diagnosis, treatment, and prognosis; contributions that explore upstream approaches to preventing stroke. We encourage articles to include strong recommendations/reflections for the clinical application of biomarkers. Papers reporting multidisciplinary findings, such as those involved in preclinical/clinical validation, are especially welcome.

Potential topics include but are not limited to the following:

  • Diagnostic and prognostic markers associated with stroke
  • Biomarkers and drug resistance in stroke treatment
  • Biomarkers and disease progression/development/risk
  • Biomarker discovery in stroke
  • Gut flora and biomarkers in stroke
  • Markers of inflammation, oxidative stress, DNA and RNA for stoke
  • Stroke biomarkers from basic to clinical

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 9754281
  • - Retraction

Retracted: Activated Hepatic Stellate Cells Promote the M1 to M2 Macrophage Transformation and Liver Fibrosis by Elevating the Histone Acetylation Level

Disease Markers
  • Special Issue
  • - Volume 2023
  • - Article ID 9823853
  • - Retraction

Retracted: Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma

Disease Markers
  • Special Issue
  • - Volume 2023
  • - Article ID 9813418
  • - Retraction

Retracted: Association between Mutation in SMARCAD1 and Basan Syndrome with Cutaneous Squamous Cell Carcinoma

Disease Markers
  • Special Issue
  • - Volume 2023
  • - Article ID 9867801
  • - Retraction

Retracted: Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11

Disease Markers
  • Special Issue
  • - Volume 2023
  • - Article ID 9861260
  • - Retraction

Retracted: Multiomics Immune-Related lncRNA Analysis of Oral Squamous Cell Carcinoma and Its Correlation with Prognosis

Disease Markers
  • Special Issue
  • - Volume 2022
  • - Article ID 4918294
  • - Research Article

[Retracted] Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma

Zengliang Wang | Wensheng Yang | ... | Bo Li
  • Special Issue
  • - Volume 2022
  • - Article ID 5382100
  • - Research Article

Long-Term Elevated Siglec-10 in Cerebral Spinal Fluid Heralds Better Prognosis for Patients with Aneurysmal Subarachnoid Hemorrhage

Sen Gao | Xun-Zhi Liu | ... | Wei Li
  • Special Issue
  • - Volume 2022
  • - Article ID 9883831
  • - Research Article

[Retracted] Activated Hepatic Stellate Cells Promote the M1 to M2 Macrophage Transformation and Liver Fibrosis by Elevating the Histone Acetylation Level

Junru Chen | Xueqing Huang | ... | Yu Cao
  • Special Issue
  • - Volume 2022
  • - Article ID 6106503
  • - Research Article

[Retracted] Multiomics Immune-Related lncRNA Analysis of Oral Squamous Cell Carcinoma and Its Correlation with Prognosis

Zhen Liu | Qian Liu | ... | Hongbo Li
  • Special Issue
  • - Volume 2022
  • - Article ID 5911408
  • - Review Article

Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Poststroke Depression: A Systematic Review and Meta-Analysis

Shirin Sarejloo | Erfan Abadifard | ... | Shokoufeh Khanzadeh
Disease Markers
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision131 days
Acceptance to publication42 days
CiteScore3.700
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

Article of the Year Award: Impactful research contributions of 2022, as selected by our Chief Editors. Discover the winning articles.